Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease
dc.contributor.author | Gonzalez-Ortiz, Fernando | |
dc.contributor.author | Kirsebom, Bjørn-Eivind Seljelid | |
dc.contributor.author | Contador, José | |
dc.contributor.author | Tanley, Jordan E. | |
dc.contributor.author | Selnes, Per | |
dc.contributor.author | Gisladottir, Berglind | |
dc.contributor.author | Pålhaugen, Lene | |
dc.contributor.author | Hemminghyth, Mathilde Suhr | |
dc.contributor.author | Jarholm, Jonas Alexander | |
dc.contributor.author | Skogseth, Ragnhild Eide | |
dc.contributor.author | Bråthen, Geir | |
dc.contributor.author | Grøndtvedt, Gøril | |
dc.contributor.author | Bjørnerud, Atle | |
dc.contributor.author | Tecelao, Sandra | |
dc.contributor.author | Waterloo, Knut | |
dc.contributor.author | Aarsland, Dag | |
dc.contributor.author | Fernández-Lebrero, Aida | |
dc.contributor.author | García-Escobar, Greta | |
dc.contributor.author | Navalpotro-Gómez, Irene | |
dc.contributor.author | Turton, Michael | |
dc.contributor.author | Hesthamar, Agnes | |
dc.contributor.author | Kac, Przemyslaw R. | |
dc.contributor.author | Nilsson, Johanna | |
dc.contributor.author | Luchsinger, Jose | |
dc.contributor.author | Hayden, Kathleen M. | |
dc.contributor.author | Harrison, Peter | |
dc.contributor.author | Puig-Pijoan, Albert | |
dc.contributor.author | Zetterberg, Henrik | |
dc.contributor.author | Hughes, Timothy M. | |
dc.contributor.author | Suárez-Calvet, Marc | |
dc.contributor.author | Karikari, Thomas K. | |
dc.contributor.author | Fladby, Tormod | |
dc.contributor.author | Blennow, Kaj | |
dc.date.accessioned | 2024-08-21T11:51:54Z | |
dc.date.available | 2024-08-21T11:51:54Z | |
dc.date.issued | 2024-04-04 | |
dc.description.abstract | Staging amyloid-beta (Aβ) pathophysiology according to the intensity of neurodegeneration could identify individuals at risk for cognitive decline in Alzheimer’s disease (AD). In blood, phosphorylated tau (p-tau) associates with Aβ pathophysiology but an AD-type neurodegeneration biomarker has been lacking. In this multicenter study (n = 1076), we show that brain-derived tau (BD-tau) in blood increases according to concomitant Aβ (“A”) and neurodegeneration (“N”) abnormalities (determined using cerebrospinal fluid biomarkers); We used blood-based A/N biomarkers to profile the participants in this study; individuals with blood-based p-tau+/BD-tau+ profiles had the fastest cognitive decline and atrophy rates, irrespective of the baseline cognitive status. Furthermore, BD-tau showed no or much weaker correlations with age, renal function, other comorbidities/risk factors and self-identified race/ethnicity, compared with other blood biomarkers. Here we show that blood-based BD-tau is a biomarker for identifying Aβ-positive individuals at risk of short-term cognitive decline and atrophy, with implications for clinical trials and implementation of anti-Aβ therapies. | en_US |
dc.identifier.citation | Gonzalez-Ortiz, Kirsebom, Contador, Tanley, Selnes, Gisladottir B, Pålhaugen, Hemminghyth, Jarholm, Skogseth, Bråthen, Grøndtvedt, Bjørnerud, Tecelao, Waterloo, Aarsland, Fernández-Lebrero, García-Escobar, Navalpotro-Gómez, Turton, Hesthamar, Kac, Nilsson, Luchsinger, Hayden, Harrison, Puig-Pijoan, Zetterberg, Hughes, Suárez-Calvet, Karikari, Fladby, Blennow. Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease. Nature Communications. 2024;15(1) | en_US |
dc.identifier.cristinID | FRIDAID 2264789 | |
dc.identifier.doi | 10.1038/s41467-024-47286-5 | |
dc.identifier.issn | 2041-1723 | |
dc.identifier.uri | https://hdl.handle.net/10037/34317 | |
dc.language.iso | eng | en_US |
dc.publisher | Springer Nature | en_US |
dc.relation.journal | Nature Communications | |
dc.rights.accessRights | openAccess | en_US |
dc.rights.holder | Copyright 2024 The Author(s) | en_US |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | en_US |
dc.rights | Attribution 4.0 International (CC BY 4.0) | en_US |
dc.title | Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease | en_US |
dc.type.version | publishedVersion | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |